Oncology

BeiGene, Bio-Thera Carve Out Bevacizumab Market

August 24th 2020

By Tony Hagen

From China to Taiwan, BeiGene and Bio-Thera Solutions hope to capture a large share of the bevacizumab biosimilar market.

Amgen, Coherus Pegfilgrastims Lose Formulary Placement

August 21st 2020

By Tony Hagen

Article

Express Scripts, the country's largest pharmacy benefit manager, has reshuffled its preferred formulary list for 2021, giving preference to fewer pegfilgrastim products than in 2020.

Samsung Bioepis' Bevacizumab Is Cleared for Launch in Europe

August 20th 2020

By Tony Hagen

Article

Samsung Bioepis' latest approval gives it 5 biosimilar approvals in the European marketplace.

Sandoz Canada Launches Ziextenzo, Riximyo

August 19th 2020

By Skylar Jeremias

Article

After receiving regulatory approval in June, Sandoz launched 2 of its biosimilars on the Canadian market.

ACCC's McBride on the Need for Biosimilar Education

August 18th 2020

By The Center for Biosimilars

Article

Ali Mcbride, PharmD, MS, BCOP, is taking a lead role in promoting the use and understanding of biosimilars in oncology.

Winegarden: Biosimilars Market Lacks Oomph

August 17th 2020

By Tony Hagen

Article

A Pacific Research Institute economist says that by his scorecard, biosimilars are not supercharging the market the way they ought to be doing .

Biosimilars Gain Market Share and Advocates Get Aboard

August 15th 2020

By Skylar Jeremias

Article

There has been an outpouring of advocacy tugging biosimilars into the marketplace, and market share of these lower-cost drugs has increased.

China Approves Henlius' Biosimilar Trastuzumab

August 14th 2020

By Tony Hagen

Article

Up-and-coming Henlius Biotech consolidates its footing in the biosimilar world with another regulatory approval.

Celltrion Refutes Critique of CT-P13 Equivalence

August 14th 2020

By Deana Ferreri, PhD

Article

Celltrion finds fault with a critique of equivalence margins used to approve its infliximab biosimilar.

Automatic Substitution Pays Off for Compass Oncology West

August 14th 2020

By Skylar Jeremias

Article

Allowing pharmacists to independently fill prescriptions with biosimilars can offer community oncology practices a way to cut costs and increase access to cancer care for patients, according to Lucy Langer, MD.